Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Experimental basing of new device for optimized UV-crosslinking: technique, efficacy and safety

Poster Details

First Author: S.Izmailova RUSSIA

Co Author(s):    B. Malyugin   D. Merzlov                 

Abstract Details

Purpose:

To evaluate efficacy of a new disrupter model epithelium-off UV-crosslinking in the experiment.

Setting:

The S. Fyodorov Eye Microsurgery Federal State Institution, Russia.

Methods:

There was developed a new disrupter model for optimized UV-crosslinking technique that allows performing a topo-guided dosed corneal epithelium scarification with graduated vacuum ring, supporting plate of working piece which is congruent to corneal surface, and spring-mechanism that allows the pins to move out for the necessary depth. The efficacy of the method was first evaluated with infrared Fourier-spectroscopy and specific reflection spectrums evaluation. The efficacy criterion was proved corneal riboflavin penetration. The safety of the method was evaluated in vivo in chinchilla rabbit breed according to re-epithelisation time, which was revealed with OCT and confocal microscopy methods.

Results:

The IR-spectroscopy method with specific reflection spectrums evaluation in the model of optimized UV-crosslinking technique revealed full-thickness corneal penetration of riboflavin. In vivo experiments showed accelerated re-epithelisation, absence of specific complications. OCT and confocal microscopy did not reveal any damage of the anterior stroma layers due to new disrupter model use.

Conclusions:

The experimental investigations of the optimized new device UV-crosslinking technique with dosed topo-guided epithelium scarification proved its efficacy and safety.

Financial Disclosure:

NONE

Back to Poster listing